Podcast: An emerging biotech’s guide to the CRO search
For a small biotech looking to make the jump into running its first clinical trial, the right CRO can be…
For a small biotech looking to make the jump into running its first clinical trial, the right CRO can be…
There’s increasingly little holding China back from catching up with the US in the country’s race to lead the world’s…
Low enrolment in clinical trials places pressure on sponsors and regulators to rethink trial design in ways that better inform…
This October will see experts meet in the biotech hub of Boston to assess the scale and solutions for the…
Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese…
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming…
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent…
The US Food and Drug Administration (FDA) has announced increased flexibility for cell and gene therapy (CGT) manufacturers, loosening quality…